Nanotechnology Now

Our NanoNews Digest Sponsors







Heifer International

Wikipedia Affiliate Button


Home > Press > Biophan reports first quarter 2008 results

Abstract:
Biophan Technologies, Inc. (OTC BB: BIPH.OB), a developer of next-generation biomedical technology, today announced the results of their operations for the first quarter ended May 30, 2008.

Biophan reports first quarter 2008 results

PITTSFORD, NY | Posted on July 17th, 2008

During the quarter ended May 30, 2008, the Company continued it's commitment to invest in the Myotech Circulatory Support System (CSS) and entered into the next stage of development, with a sharpened focus on the acute resuscitation market segment, where there is a large patient population not adequately served by existing technologies. In addition, Myotech secured a Memorandum of Understanding with PPA Technologies in Germany, a potential strategic partner for the development of the Myotech Circulatory Support System, which Biophan expects to be approved for sale in the US, in 24-30 months.

Biophan also expanded its intellectual property through the acquisition of the patent portfolio from Nanoset, LLC, which provides broad coverage on novel medical uses of nanomagnetic materials. And, the Company saw the issuance of two new patents expanding coverage of the biothermal power supply and providing coverage for an optical MRI catheter system, which is a continuation of its core strategy of pursuing grants and strategic partnerships for the development of its earlier stage technologies.

The Company ended the quarter with $5.7 million in cash, and recognized revenue from license fees and testing and consulting services of $0.22 million.

####

About Biophan Technologies, Inc.
Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 70% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For more information, please click here

Contacts:
Carolyn Hotchkiss
Communications Manager
Biophan Technologies, Inc.
(585) 267-4800

Copyright © Biophan Technologies, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

Announcements

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

Patents/IP/Tech Transfer/Licensing

Nanoparticle Opens the Door to Clean-Energy Alternatives June 14th, 2013

DRYWIRED™ Receives MILITARY-STANDARD Certifications from QUANTA LABORATORIES for Its Latest Protective Nano-Coating Technology June 5th, 2013

Apple patents point to slimmer battery tech June 1st, 2013

Patent for Coaxial Nanofibre Production: Scientists from Contipro have patented new jet for effective coaxial nanofibers production May 31st, 2013

Financial Reports

Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013

Harris & Harris Group Reports Financial Statements as of March 31, 2013 May 10th, 2013

Arrowhead Reports Fiscal 2013 Second Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time May 9th, 2013

Arrowhead to Report Fiscal 2013 Second Quarter Financial Results - Conference Call Scheduled for Thursday, May 9, 2013 May 2nd, 2013

Acquisitions/Mergers/Splits

AXEON Acquires Assets of Leading Reverse Osmosis Systems Manufacturer June 17th, 2013

Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013

Element Six Acquires the Assets and Intellectual Property of Group4 Labs, Inc to Expand Portfolio of Synthetic Diamond Materials for the Semiconductor Industry May 31st, 2013

Mincom Capital Inc. and Group Nanoxplore Inc. Sign Letter of Intent for a Qualifying Transaction April 10th, 2013

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project








abbigliamento uomo
Computer Accessories
© Copyright 1999-2013 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE